Oncohost
Leveraging proteomic pattern analysis to personalize cancer treatment and improve patient outcomes.
About
OncoHost's PROphet® platform uses bioinformatic proteomic pattern recognition and AI to generate a personalized PROphet® score, predicting the benefit of PD-1/PD-L1 inhibitors. This blood-based test provides an all-inclusive evaluation of the tumor and host microenvironment to aid clinical decision-making and improve patient outcomes. The company serves patients, providers, and pharmaceutical partners. Teams look it up for Healthcare, Pharmaceutical, Oncology.
Frequently asked
What does Oncohost do?
Oncohost is a Healthcare company that offers Software. Teams look it up for Pharmaceutical, Oncology, Cancer. It is based in Tel Aviv, Israel and was founded in 2017. Public records show about 46 people and $43M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Oncohost raised?
Oncohost has raised a total of $43M in funding. The most recent round on record is Series C.
Where is Oncohost headquartered?
Oncohost is headquartered in Tel Aviv, Israel.
When was Oncohost founded?
Oncohost was founded in 2017.
What industry does Oncohost operate in?
Oncohost operates in Healthcare, Pharmaceutical, Oncology, Cancer, Proteomics.
How many employees does Oncohost have?
Oncohost has approximately 46 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.